<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757952</url>
  </required_header>
  <id_info>
    <org_study_id>PINE-A-14183</org_study_id>
    <secondary_id>CDR0000614811</secondary_id>
    <secondary_id>UCSF-H105-31440-01</secondary_id>
    <nct_id>NCT00757952</nct_id>
  </id_info>
  <brief_title>Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction</brief_title>
  <official_title>Early Detection of Epithelial Ovarian Cancer Using Exhaled Breath Markers: GC/FT-ICR Mass Spectrometry and Canine Olfaction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pine Street Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pine Street Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of exhaled breath from patients with ovarian epithelial cancer,&#xD;
      polycystic ovarian syndrome, or endometriosis and from healthy participants in the laboratory&#xD;
      may help doctors identify and learn more about biomarkers related to cancer. It may also help&#xD;
      doctors find and diagnose ovarian epithelial cancer sooner, when it may be easier to treat.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying exhaled breath biomarkers to see how well they find&#xD;
      ovarian epithelial cancer in patients with newly diagnosed ovarian epithelial cancer,&#xD;
      polycystic ovarian syndrome, or endometriosis and in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify patterns of exhaled compounds in breath samples from patients with newly&#xD;
           diagnosed ovarian epithelial cancer that are significantly and reproducibility different&#xD;
           from those of healthy volunteers using gas chromatography Fourier transform ion&#xD;
           cyclotron resonance mass spectrometry (GC/FT-ICR MS).&#xD;
&#xD;
        -  Train five canines to discriminate between exhaled breath samples from patients with&#xD;
           newly diagnosed ovarian epithelial cancer and healthy volunteers.&#xD;
&#xD;
        -  Use both canine olfaction and GC/FT-ICR MS to distinguish between exhaled breath samples&#xD;
           from patients with newly diagnosed ovarian epithelial cancer and patients with&#xD;
           polycystic ovarian syndrome or endometriosis.&#xD;
&#xD;
        -  Repeat breath sampling in patients with newly diagnosed ovarian epithelial cancer&#xD;
           throughout the course of diagnosis and therapy.&#xD;
&#xD;
      OUTLINE: Exhaled breath samples are collected from patients and healthy volunteers. The&#xD;
      samples are analyzed by gas chromatography Fourier transform ion cyclotron resonance mass&#xD;
      spectrometry (GC/FT-ICR MS) to determine chemical compositions, identities, and predictive&#xD;
      patterns of biomarkers in exhaled breath condensate. GC/FT-ICR MS and trained canine&#xD;
      olfaction are used to distinguish between exhaled breath samples from patients with ovarian&#xD;
      epithelial cancer, patients with polycystic ovarian syndrome or endometriosis, and healthy&#xD;
      volunteers.&#xD;
&#xD;
      Patients and healthy volunteers complete questionnaires about BRCA 1 and BRCA 2 status (if&#xD;
      known), alcohol use, smoking (including duration and type of cigarettes), physical activity&#xD;
      (duration and type), socioeconomic status, education, county of residence, age at menopause&#xD;
      (if applicable), age at menarche, presence of first- and second-degree family history of&#xD;
      breast cancer or ovarian epithelial cancer, body mass index (height and weight), and&#xD;
      co-morbidities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of patterns of exhaled compounds in breath samples using gas chromatography Fourier transform ion cyclotron resonance mass spectrometry (GC/FT-ICR MS)</measure>
    <time_frame>2009-2012</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of GC/FT-ICR MS in distinguishing between exhaled breath samples from patients with ovarian epithelial cancer, patients with polycystic ovarian syndrome or endometriosis, and healthy volunteers</measure>
    <time_frame>2009-2012</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of canine scent detection in distinguishing between exhaled breath samples from patients with ovarian epithelial cancer and healthy volunteers</measure>
    <time_frame>2009-2012</time_frame>
  </primary_outcome>
  <enrollment type="Actual">109</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fourier transform ion cyclotron resonance mass spectrometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Histologically confirmed ovarian epithelial cancer.&#xD;
&#xD;
          2. Polycystic Ovarian Syndrome or Endometriosis&#xD;
&#xD;
          3. Healthy Controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets one of the following criteria:&#xD;
&#xD;
               -  Histologically confirmed ovarian epithelial cancer&#xD;
&#xD;
                    -  Newly diagnosed disease&#xD;
&#xD;
               -  Diagnosis of polycystic ovarian syndrome or endometriosis&#xD;
&#xD;
               -  Healthy volunteer meeting all of the following criteria:&#xD;
&#xD;
                    -  No prior ovarian cancer (including invasive ovarian epithelial cancer,&#xD;
                       fallopian tube cancer, or primary papillary serous carcinoma of the&#xD;
                       peritoneum)&#xD;
&#xD;
                    -  No prior breast cancer (including ductal carcinoma in situ [DCIS])&#xD;
&#xD;
                    -  No prior ovarian or breast cancer (including DCIS) in any first- or&#xD;
                       second-degree relative&#xD;
&#xD;
                    -  BRCA1 or BRCA2 mutation negative (if known) OR no first- or second-degree&#xD;
                       relative with a BRCA1 or BRCA2 mutation (if known)&#xD;
&#xD;
          -  No prior diagnosis of cancer&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Lives in California and close to the study sampling centers&#xD;
&#xD;
          -  Reads and writes English, Spanish, or Chinese&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
          -  Willing to provide breath samples&#xD;
&#xD;
          -  No alcohol intake within the past 3 days&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 3 days since prior Cox-2 inhibitors, vitamin E, omega-3 fatty acids,&#xD;
             antioxidants, bromelain, coenzyme Q10, curcumin, or vitamin A&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael McCulloch, MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pine Street Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pine Street Foundation</name>
      <address>
        <city>San Anselmo</city>
        <state>California</state>
        <zip>94960-2674</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center - California Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maine</name>
      <address>
        <city>Orono</city>
        <state>Maine</state>
        <zip>04469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>September 22, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pine Street Foundation</investigator_affiliation>
    <investigator_full_name>Michael McCulloch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

